Review



mouse anti human iga2 hrp  (SouthernBiotech)


Bioz Verified Symbol SouthernBiotech is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    SouthernBiotech mouse anti human iga2 hrp
    Mouse Anti Human Iga2 Hrp, supplied by SouthernBiotech, used in various techniques. Bioz Stars score: 94/100, based on 35 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse anti human iga2 hrp/product/SouthernBiotech
    Average 94 stars, based on 35 article reviews
    mouse anti human iga2 hrp - by Bioz Stars, 2026-05
    94/100 stars

    Images



    Similar Products

    iga2 fitc  (Miltenyi Biotec)
    96
    Miltenyi Biotec iga2 fitc
    The B cell isotypes in the LN and PB compartment, the horizontal black lines indicate the average percentage in both compartments ( a ) IgM in switched B cells, lower in LNs than in PB at 8% (IQR: 5% − 11%) or 13% (IQR: 11% − 26%) ( p = 0.0001), respectively; ( b ) IgM in S-binding B cells, no difference between the LNs and PB at 29% (IQR: 16% − 51%) or 15% (IQR 6% − 33%) ( p = 0.058), respectively; ( c ) <t>IgA</t> in switched B cells, no difference between LNs and PB at 36% (IQR 27% − 43%) or 37% (IQR 32% − 43%) ( p = 0.207), respectively; ( d ) IgA in S-binding B cells, in LNs higher than in PB at 22% (IQR 11% − 32%) or 8% (IQR 5% − 15%) ( p = 0.0002), respectively; ( e ) IgG in switched B cells, in LNs higher than in PB at 49% (IQR 42% − 53%) or 42% (IQR 32% − 48%) ( p = 0.0110), respectively; ( f ) IgG in S-binding B cells, in LNs lower than in PB at 53% (IQR: 44% − 67%) or 73% (IQR 61% − 80%) ( p = 0.0001), respectively. PRM (primary), two vaccinations; BST (booster three), three vaccinations; BSF (booster four), four vaccinations; INFX (infection), prior infection; HYB (hybrid), immunity in which the infection was prior to the last of two vaccinations.
    Iga2 Fitc, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/iga2 fitc/product/Miltenyi Biotec
    Average 96 stars, based on 1 article reviews
    iga2 fitc - by Bioz Stars, 2026-05
    96/100 stars
    		  Buy from Supplier
    mouse anti human iga2 hrp  (SouthernBiotech)
    94
    SouthernBiotech mouse anti human iga2 hrp
    The B cell isotypes in the LN and PB compartment, the horizontal black lines indicate the average percentage in both compartments ( a ) IgM in switched B cells, lower in LNs than in PB at 8% (IQR: 5% − 11%) or 13% (IQR: 11% − 26%) ( p = 0.0001), respectively; ( b ) IgM in S-binding B cells, no difference between the LNs and PB at 29% (IQR: 16% − 51%) or 15% (IQR 6% − 33%) ( p = 0.058), respectively; ( c ) <t>IgA</t> in switched B cells, no difference between LNs and PB at 36% (IQR 27% − 43%) or 37% (IQR 32% − 43%) ( p = 0.207), respectively; ( d ) IgA in S-binding B cells, in LNs higher than in PB at 22% (IQR 11% − 32%) or 8% (IQR 5% − 15%) ( p = 0.0002), respectively; ( e ) IgG in switched B cells, in LNs higher than in PB at 49% (IQR 42% − 53%) or 42% (IQR 32% − 48%) ( p = 0.0110), respectively; ( f ) IgG in S-binding B cells, in LNs lower than in PB at 53% (IQR: 44% − 67%) or 73% (IQR 61% − 80%) ( p = 0.0001), respectively. PRM (primary), two vaccinations; BST (booster three), three vaccinations; BSF (booster four), four vaccinations; INFX (infection), prior infection; HYB (hybrid), immunity in which the infection was prior to the last of two vaccinations.
    Mouse Anti Human Iga2 Hrp, supplied by SouthernBiotech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse anti human iga2 hrp/product/SouthernBiotech
    Average 94 stars, based on 1 article reviews
    mouse anti human iga2 hrp - by Bioz Stars, 2026-05
    94/100 stars
    		  Buy from Supplier
    anti iga2  (SouthernBiotech)
    93
    SouthernBiotech anti iga2
    The B cell isotypes in the LN and PB compartment, the horizontal black lines indicate the average percentage in both compartments ( a ) IgM in switched B cells, lower in LNs than in PB at 8% (IQR: 5% − 11%) or 13% (IQR: 11% − 26%) ( p = 0.0001), respectively; ( b ) IgM in S-binding B cells, no difference between the LNs and PB at 29% (IQR: 16% − 51%) or 15% (IQR 6% − 33%) ( p = 0.058), respectively; ( c ) <t>IgA</t> in switched B cells, no difference between LNs and PB at 36% (IQR 27% − 43%) or 37% (IQR 32% − 43%) ( p = 0.207), respectively; ( d ) IgA in S-binding B cells, in LNs higher than in PB at 22% (IQR 11% − 32%) or 8% (IQR 5% − 15%) ( p = 0.0002), respectively; ( e ) IgG in switched B cells, in LNs higher than in PB at 49% (IQR 42% − 53%) or 42% (IQR 32% − 48%) ( p = 0.0110), respectively; ( f ) IgG in S-binding B cells, in LNs lower than in PB at 53% (IQR: 44% − 67%) or 73% (IQR 61% − 80%) ( p = 0.0001), respectively. PRM (primary), two vaccinations; BST (booster three), three vaccinations; BSF (booster four), four vaccinations; INFX (infection), prior infection; HYB (hybrid), immunity in which the infection was prior to the last of two vaccinations.
    Anti Iga2, supplied by SouthernBiotech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti iga2/product/SouthernBiotech
    Average 93 stars, based on 1 article reviews
    anti iga2 - by Bioz Stars, 2026-05
    93/100 stars
    		  Buy from Supplier
    mouse anti human iga2 biot  (SouthernBiotech)
    93
    SouthernBiotech mouse anti human iga2 biot
    The B cell isotypes in the LN and PB compartment, the horizontal black lines indicate the average percentage in both compartments ( a ) IgM in switched B cells, lower in LNs than in PB at 8% (IQR: 5% − 11%) or 13% (IQR: 11% − 26%) ( p = 0.0001), respectively; ( b ) IgM in S-binding B cells, no difference between the LNs and PB at 29% (IQR: 16% − 51%) or 15% (IQR 6% − 33%) ( p = 0.058), respectively; ( c ) <t>IgA</t> in switched B cells, no difference between LNs and PB at 36% (IQR 27% − 43%) or 37% (IQR 32% − 43%) ( p = 0.207), respectively; ( d ) IgA in S-binding B cells, in LNs higher than in PB at 22% (IQR 11% − 32%) or 8% (IQR 5% − 15%) ( p = 0.0002), respectively; ( e ) IgG in switched B cells, in LNs higher than in PB at 49% (IQR 42% − 53%) or 42% (IQR 32% − 48%) ( p = 0.0110), respectively; ( f ) IgG in S-binding B cells, in LNs lower than in PB at 53% (IQR: 44% − 67%) or 73% (IQR 61% − 80%) ( p = 0.0001), respectively. PRM (primary), two vaccinations; BST (booster three), three vaccinations; BSF (booster four), four vaccinations; INFX (infection), prior infection; HYB (hybrid), immunity in which the infection was prior to the last of two vaccinations.
    Mouse Anti Human Iga2 Biot, supplied by SouthernBiotech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse anti human iga2 biot/product/SouthernBiotech
    Average 93 stars, based on 1 article reviews
    mouse anti human iga2 biot - by Bioz Stars, 2026-05
    93/100 stars
    		  Buy from Supplier
    beads  (SouthernBiotech)
    93
    SouthernBiotech beads
    The B cell isotypes in the LN and PB compartment, the horizontal black lines indicate the average percentage in both compartments ( a ) IgM in switched B cells, lower in LNs than in PB at 8% (IQR: 5% − 11%) or 13% (IQR: 11% − 26%) ( p = 0.0001), respectively; ( b ) IgM in S-binding B cells, no difference between the LNs and PB at 29% (IQR: 16% − 51%) or 15% (IQR 6% − 33%) ( p = 0.058), respectively; ( c ) <t>IgA</t> in switched B cells, no difference between LNs and PB at 36% (IQR 27% − 43%) or 37% (IQR 32% − 43%) ( p = 0.207), respectively; ( d ) IgA in S-binding B cells, in LNs higher than in PB at 22% (IQR 11% − 32%) or 8% (IQR 5% − 15%) ( p = 0.0002), respectively; ( e ) IgG in switched B cells, in LNs higher than in PB at 49% (IQR 42% − 53%) or 42% (IQR 32% − 48%) ( p = 0.0110), respectively; ( f ) IgG in S-binding B cells, in LNs lower than in PB at 53% (IQR: 44% − 67%) or 73% (IQR 61% − 80%) ( p = 0.0001), respectively. PRM (primary), two vaccinations; BST (booster three), three vaccinations; BSF (booster four), four vaccinations; INFX (infection), prior infection; HYB (hybrid), immunity in which the infection was prior to the last of two vaccinations.
    Beads, supplied by SouthernBiotech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/beads/product/SouthernBiotech
    Average 93 stars, based on 1 article reviews
    beads - by Bioz Stars, 2026-05
    93/100 stars
    		  Buy from Supplier
    house production mouse anti human iga2  (SouthernBiotech)
    93
    SouthernBiotech house production mouse anti human iga2
    The B cell isotypes in the LN and PB compartment, the horizontal black lines indicate the average percentage in both compartments ( a ) IgM in switched B cells, lower in LNs than in PB at 8% (IQR: 5% − 11%) or 13% (IQR: 11% − 26%) ( p = 0.0001), respectively; ( b ) IgM in S-binding B cells, no difference between the LNs and PB at 29% (IQR: 16% − 51%) or 15% (IQR 6% − 33%) ( p = 0.058), respectively; ( c ) <t>IgA</t> in switched B cells, no difference between LNs and PB at 36% (IQR 27% − 43%) or 37% (IQR 32% − 43%) ( p = 0.207), respectively; ( d ) IgA in S-binding B cells, in LNs higher than in PB at 22% (IQR 11% − 32%) or 8% (IQR 5% − 15%) ( p = 0.0002), respectively; ( e ) IgG in switched B cells, in LNs higher than in PB at 49% (IQR 42% − 53%) or 42% (IQR 32% − 48%) ( p = 0.0110), respectively; ( f ) IgG in S-binding B cells, in LNs lower than in PB at 53% (IQR: 44% − 67%) or 73% (IQR 61% − 80%) ( p = 0.0001), respectively. PRM (primary), two vaccinations; BST (booster three), three vaccinations; BSF (booster four), four vaccinations; INFX (infection), prior infection; HYB (hybrid), immunity in which the infection was prior to the last of two vaccinations.
    House Production Mouse Anti Human Iga2, supplied by SouthernBiotech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/house production mouse anti human iga2/product/SouthernBiotech
    Average 93 stars, based on 1 article reviews
    house production mouse anti human iga2 - by Bioz Stars, 2026-05
    93/100 stars
    		  Buy from Supplier
    house production mouse anti human iga2  (Valiant Co Ltd)
    96
    Valiant Co Ltd house production mouse anti human iga2
    The B cell isotypes in the LN and PB compartment, the horizontal black lines indicate the average percentage in both compartments ( a ) IgM in switched B cells, lower in LNs than in PB at 8% (IQR: 5% − 11%) or 13% (IQR: 11% − 26%) ( p = 0.0001), respectively; ( b ) IgM in S-binding B cells, no difference between the LNs and PB at 29% (IQR: 16% − 51%) or 15% (IQR 6% − 33%) ( p = 0.058), respectively; ( c ) <t>IgA</t> in switched B cells, no difference between LNs and PB at 36% (IQR 27% − 43%) or 37% (IQR 32% − 43%) ( p = 0.207), respectively; ( d ) IgA in S-binding B cells, in LNs higher than in PB at 22% (IQR 11% − 32%) or 8% (IQR 5% − 15%) ( p = 0.0002), respectively; ( e ) IgG in switched B cells, in LNs higher than in PB at 49% (IQR 42% − 53%) or 42% (IQR 32% − 48%) ( p = 0.0110), respectively; ( f ) IgG in S-binding B cells, in LNs lower than in PB at 53% (IQR: 44% − 67%) or 73% (IQR 61% − 80%) ( p = 0.0001), respectively. PRM (primary), two vaccinations; BST (booster three), three vaccinations; BSF (booster four), four vaccinations; INFX (infection), prior infection; HYB (hybrid), immunity in which the infection was prior to the last of two vaccinations.
    House Production Mouse Anti Human Iga2, supplied by Valiant Co Ltd, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/house production mouse anti human iga2/product/Valiant Co Ltd
    Average 96 stars, based on 1 article reviews
    house production mouse anti human iga2 - by Bioz Stars, 2026-05
    96/100 stars
    		  Buy from Supplier
    a9604d2 southern biotech cat  (SouthernBiotech)
    94
    SouthernBiotech a9604d2 southern biotech cat
    The B cell isotypes in the LN and PB compartment, the horizontal black lines indicate the average percentage in both compartments ( a ) IgM in switched B cells, lower in LNs than in PB at 8% (IQR: 5% − 11%) or 13% (IQR: 11% − 26%) ( p = 0.0001), respectively; ( b ) IgM in S-binding B cells, no difference between the LNs and PB at 29% (IQR: 16% − 51%) or 15% (IQR 6% − 33%) ( p = 0.058), respectively; ( c ) <t>IgA</t> in switched B cells, no difference between LNs and PB at 36% (IQR 27% − 43%) or 37% (IQR 32% − 43%) ( p = 0.207), respectively; ( d ) IgA in S-binding B cells, in LNs higher than in PB at 22% (IQR 11% − 32%) or 8% (IQR 5% − 15%) ( p = 0.0002), respectively; ( e ) IgG in switched B cells, in LNs higher than in PB at 49% (IQR 42% − 53%) or 42% (IQR 32% − 48%) ( p = 0.0110), respectively; ( f ) IgG in S-binding B cells, in LNs lower than in PB at 53% (IQR: 44% − 67%) or 73% (IQR 61% − 80%) ( p = 0.0001), respectively. PRM (primary), two vaccinations; BST (booster three), three vaccinations; BSF (booster four), four vaccinations; INFX (infection), prior infection; HYB (hybrid), immunity in which the infection was prior to the last of two vaccinations.
    A9604d2 Southern Biotech Cat, supplied by SouthernBiotech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/a9604d2 southern biotech cat/product/SouthernBiotech
    Average 94 stars, based on 1 article reviews
    a9604d2 southern biotech cat - by Bioz Stars, 2026-05
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    The B cell isotypes in the LN and PB compartment, the horizontal black lines indicate the average percentage in both compartments ( a ) IgM in switched B cells, lower in LNs than in PB at 8% (IQR: 5% − 11%) or 13% (IQR: 11% − 26%) ( p = 0.0001), respectively; ( b ) IgM in S-binding B cells, no difference between the LNs and PB at 29% (IQR: 16% − 51%) or 15% (IQR 6% − 33%) ( p = 0.058), respectively; ( c ) IgA in switched B cells, no difference between LNs and PB at 36% (IQR 27% − 43%) or 37% (IQR 32% − 43%) ( p = 0.207), respectively; ( d ) IgA in S-binding B cells, in LNs higher than in PB at 22% (IQR 11% − 32%) or 8% (IQR 5% − 15%) ( p = 0.0002), respectively; ( e ) IgG in switched B cells, in LNs higher than in PB at 49% (IQR 42% − 53%) or 42% (IQR 32% − 48%) ( p = 0.0110), respectively; ( f ) IgG in S-binding B cells, in LNs lower than in PB at 53% (IQR: 44% − 67%) or 73% (IQR 61% − 80%) ( p = 0.0001), respectively. PRM (primary), two vaccinations; BST (booster three), three vaccinations; BSF (booster four), four vaccinations; INFX (infection), prior infection; HYB (hybrid), immunity in which the infection was prior to the last of two vaccinations.

    Journal: Scientific Reports

    Article Title: SARS-CoV-2-specific B cell responses in non-draining lymph nodes and antibody functionalities in immunized end-stage renal disease patients

    doi: 10.1038/s41598-025-27815-y

    Figure Lengend Snippet: The B cell isotypes in the LN and PB compartment, the horizontal black lines indicate the average percentage in both compartments ( a ) IgM in switched B cells, lower in LNs than in PB at 8% (IQR: 5% − 11%) or 13% (IQR: 11% − 26%) ( p = 0.0001), respectively; ( b ) IgM in S-binding B cells, no difference between the LNs and PB at 29% (IQR: 16% − 51%) or 15% (IQR 6% − 33%) ( p = 0.058), respectively; ( c ) IgA in switched B cells, no difference between LNs and PB at 36% (IQR 27% − 43%) or 37% (IQR 32% − 43%) ( p = 0.207), respectively; ( d ) IgA in S-binding B cells, in LNs higher than in PB at 22% (IQR 11% − 32%) or 8% (IQR 5% − 15%) ( p = 0.0002), respectively; ( e ) IgG in switched B cells, in LNs higher than in PB at 49% (IQR 42% − 53%) or 42% (IQR 32% − 48%) ( p = 0.0110), respectively; ( f ) IgG in S-binding B cells, in LNs lower than in PB at 53% (IQR: 44% − 67%) or 73% (IQR 61% − 80%) ( p = 0.0001), respectively. PRM (primary), two vaccinations; BST (booster three), three vaccinations; BSF (booster four), four vaccinations; INFX (infection), prior infection; HYB (hybrid), immunity in which the infection was prior to the last of two vaccinations.

    Article Snippet: The following surface mAbs were used: CD19 BV785, CD20 APC-Fire750, CD27 BB700, IgD PE-CF594, CD24 BV650, CD38 BUV563, IgM BUV395, IgG BUV496 (all from BD Biosciences), CXCR3 R718 (eBioscience), IgG1 PE, IgG2 PE, IgG2 FITC, IgG3 FITC (all from SouthernBiotech), IgA PE-Vio770, IgA2 FITC (both from Miltenyi Biotec), and IgA1 PE (Abcam).

    Techniques: Binding Assay, Infection